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esponsibility of Xi’Abstract A novel, fast, sensitive and robust method based on ultra-performance liquid chromatography
coupled to atmospheric pressure electrospray ionization tandem mass spectrometry (UPLC–ESI-MS/MS)
has been developed to separate two Tibolone stereoisomers i.e., 3α-Hydroxy Tibolone and 3β-Hydroxy
Tibolone and to quantify 3α-Hydroxy Tibolone using p-toulenesulfonyl isocyanate (PTSI) as a
derivatizing reagent in human plasma. 3α-Hydroxy Tibolone-13CD3 was used as an internal standard
(IS). The analyte and IS were extracted from human plasma by liquid–liquid extraction using ethyl
acetate. Extracted samples were analyzed by UPLC–ESI-MS/MS. Chromatography was performed using
binary gradient on UPLC analytical column. A linear calibration curve over the range of 0.100–35.000 ng/
mL was obtained and lower limit of quantiﬁcation (LLOQ) was 0.100 ng/mL demonstrating acceptable
accuracy and precision. This method was successfully applied to a pharmacokinetic study in order to
compare a test Tibolone 2.5 mg formulation vs. a reference 2.5 mg Tibolone tablet formulation in 50 post-sity. Production and hosting by Elsevier B.V. All rights reserved.
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Application of UPLC–MS/MS for separation and quantiﬁcation of 3a-Hydroxy Tibolone 271menopausal/surgical menopause female human volunteers under fasting conditions. It is concluded that
test formulation of Tibolone is bioequivalent to reference formulation of Tibolone.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Tibolone substitutes for the loss of estrogen production in post-
menopausal women and alleviates menopausal symptoms [1,2]. It has
estrogenic effects on the vagina, bone and the thermoregulatory
centers in the brain (hot ﬂushes) [3,4] and it is also used in the
prevention of osteoporosis when intolerant of, or contraindicated for,
other medical products approved for the prevention of osteoporosis.
After oral administration Tibolone is rapidly metabolized into
three compounds [5] which contribute to the pharmacological
effects of Tibolone. Two of these metabolites (3α-Hydroxy
Tibolone and 3β-Hydroxy Tibolone) have predominantly an
estrogenic effect [3,6,7]; a third metabolite (Δ4 isomer of
Tibolone) and the parent compound have predominantly proges-
trogenic and androgenic activities [6,7]. Due to rapid metabolism,
the plasma levels of Tibolone and Δ4 isomer of Tibolone are very
low. As peak plasma levels of 3α-Hydroxy Tibolone are high it
was monitored to determine the pharmacokinetic parameters [5].
Several methods have been reported on quantiﬁcation of Tibolone
with and without its metabolites in different biological matrices.
Timmer et al. [5] applied gas chromatography–mass spectrometry
(GC–MS) method described by Verhoeven et al. [8] for quantiﬁcation
of Tibolone and its metabolites in pharmacokinetic study of Tibolone
in human plasma demonstrating LLOQ 0.100 ng/mL without any
method validation details. Kang and Kim [9] developed solid phase
extraction (SPE) GC–MS method for quantiﬁcation of 3α-Hydroxy
Tibolone and 3β-Hydroxy Tibolone in plasma with LLOQ 0.500 ng/
mL. Verheul et al. [10] reported GC–MS method for quantiﬁcation of
Tibolone and its metabolites from monkey plasma (LLOQ 0.100 ng/
mL) and urine (LLOQ 0.500 ng/mL) which involved a solid phase
extraction followed by derivatisation of samples. The method applied
was validated for human serum and some important experiments like
matrix effect, hemolysis effect and relevant stabilities were not
performed during validation.
Literature survey indicated wide use of GC–MS technique in
analysis of Tibolone and its metabolites compared to liquid chroma-
tography–mass spectrometry (LC–MS) or LC–MS/MS technique.
Zacharia et al. [11] reported a need to employ the LC–MS method
for quantiﬁcation of Tibolone as in the GC–MS method Tibolone gets
converted to 7α-methyl-ethinyl estradiol. Nevertheless, liquid chroma-
tography coupled with atmospheric ionization mass spectrometry is a
highly sensitive and selective technique compared to other techniques
[12,13]. Zuo et al. [14] reported an LC–MS method for quantiﬁcation
of 3α-Hydroxy Tibolone and 3β-Hydroxy Tibolone in human plasma.
This method was quite time consuming because its long run time and
high injection volume lead to column blockage after continuous
injections. Use of high plasma volume requires more blood sample
collection from volunteers and results in higher matrix effect during
sample preparation. Some of the parameters like matrix effect,
hemolysis effect, stability of analytes in plasma and solution form,
incurred sample reanalysis were not discussed, which play an
important role during bioanalysis.
In view of these limitations, it was important to develop and validate
a rapid and reliable bioanalytical method for quantiﬁcation of major
Tibolone metabolite i.e., 3α-Hydroxy Tibolone in human plasma usingLC–MS/MS which will be more selective and sensitive than earlier
reported GC–MS and LC–MS methods. The present method devel-
oped has a run time of 5 min, which shows high throughput because of
its ability to acquire large number of biological samples in a single day.
Use of 0.500 mL plasma volume greatly reduces the matrix effect and
improves the compliance of volunteers in process of blood sample
collection. Less injection volume (10 mL) helps in retaining the
chromatographic performance of column, for large number of injec-
tions and thus extends its lifetime. Usage of less mobile phase ﬂow rate
indicates the low solvent consumption. Deuterated IS helps in
improving accuracy and precision of the method. The method
developed was fully validated as per regulatory requirements and
successfully applied to comparative bioavailability study of two
tibolone formulations.2. Experimental
2.1. Chemicals and reagents
3α-Hydroxy Tibolone and 3α-Hydroxy Tibolone-13CD3 (IS) were
provided by Toronto Research Chemicals Inc. (Lot Number 13-SHG-
55-1 and 17-SHG-167-3 respectively). Acetonitrile and methanol (J.T.
Baker, HPLC grade) were purchased from RFCL Limited, New Delhi,
India. Ammonium acetate and p-toulenesulfonyl isocyanate (PTSI)
were obtained from Sigma-ALDRICH Co., USA. Ethyl acetate was
provided by s d FINE-CHEM Limited, Mumbai, India. Water was
used from in-house MilliQ® Gradient A-10® system made in France.
Plasma was obtained by centrifugation of blood treated with the
anticoagulant K3EDTA.
2.2. Calibration standards and quality control samples
Stock and working solutions of 3α-Hydroxy Tibolone and 3α-
Hydroxy Tibolone-13CD3 were prepared in appropriate solvent.
Calibration standards for 3α-Hydroxy Tibolone were prepared by
spiking blank plasma with working solutions to obtain the ﬁnal
concentrations of 0.100, 0.200, 0.500, 2.500, 7.000, 14.000,
21.000, 28.000, 35.000 ng/mL. Quality control samples were
prepared in blank plasma at concentrations of 0.280 (quality
control at low level, QCL), 4.500 (quality control at medium level
one, QCM1), 12.500 (quality control at medium level two,
QCM2), and 26.250 ng/mL (quality control at high level, QCH).
The spiked plasma samples (standards and quality controls) were
extracted in each batch of sample analysis.
2.3. Sample preparation
All frozen human plasma samples were initially thawed at room
temperature. A 500 mL volume of human plasma sample was
introduced into a tarsons centrifuge tube having conical bottom,
followed by 25 mL of internal standard solution (160 ng/mL of 3α-
Hydroxy Tibolone-13CD3). After vortexing for 30 s ethyl acetate was
added (3 mL) to all the tubes and extraction was performed by shaking
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shaking, all the samples were centrifuged at 3200 rpm at 10 1C for
5 min. The upper organic layer was transferred to polypropylene tubes.
Then samples were dried under nitrogen ﬂux at 45 1C for 20 min.
Dried extract was reconstituted with 60 mL of acetonitrile. Samples
were derivatized by addition of 50 mL of PTSI in acetonitrile and
vortexing for 2 min. 100 mL of 2 mM ammonium acetate was added
and vortexed for 30 s to stop the derivatization.
2.4. Chromatographic conditions
Derivatized samples (10 mL) were injected into an ACQUITY UPLC®
BEH C18 1.7 mm (2.1 mm 100 mm) analytical column operating at
30 1C. The compounds were eluted by pumping mobile phase,
methanol (70%) and 2 mM ammonium acetate (30%) using binary
pumps at a ﬂow rate of 0.220 mL/min. The temperature of autosampler
was kept at 5 1C and the run time was 5 min.
2.5. Mass spectrometer conditions
MS detection was performed in the negative ESI mode on Waters
Quattro Premier XE (MICROMASS® MS TECHNOLOGIES,
UK) tandem mass spectrometer.
Source parameters and compound parameters were optimized
during the infusion of derivatized product of 3α-Hydroxy Tibolone
and 3α-Hydroxy Tibolone-13CD3 through the interface connected
with the Acquity UPLC System (Waters) and were as follows:
Capillary, −4.20 kV; Extractor, −6.00 V; RF Lens, −0.1 V; source
temperature, −130 1C; desolvation temperature, −420 1C; deso-
lvation gas ﬂow, −1150 L/h; cone gas ﬂow, −10 L/h.
For 3α-Hydroxy Tibolone cone voltage was set at 50.00 V and
collision energy at 32.00 eV, whereas for 3α-Hydroxy Tibolone-13CD3
cone voltage was set at 47.00 V and collision energy at 31.00 eV.
Multiple reaction monitoring (MRM) was used for the detection
of 3α-Hydroxy Tibolone and 3α-Hydroxy Tibolone-13CD3.The m/
z 510.2-170.0 (Fig. 1) transition was monitored for 3α-Hydroxy
Tibolone and the m/z 514.2-170.0 (Fig. 2) transition for 3α-
Hydroxy Tibolone-13CD3. Data acquisition and analysis were
performed using the software MassLynx Version 4.1
2.6. Method validation
All sample analyses were carried out in a GLP-compliant manner
and in accordance to the current Brazilian regulatory agency
requirements, National Health Surveillance Agency (ANVISA)
[15], and the US Food and Drug Administration Bioanalytical
Method Validation guidance [16].
2.6.1. Linearity
The standard calibration curves were constructed using the peak
area ratios of 3α-Hydroxy Tibolone and IS vs. 3α-Hydroxy
Tibolone nominal concentrations of the nine plasma standards
(0.100, 0.200, 0.500, 2.500, 7.000, 14.000, 21.000, 28.000,
35.000 ng/mL). Linear regression with weighting factor 1/x2 was
performed to assess the linearity. In addition, a blank (non-spiked
sample) and a zero plasma sample (only spiked with IS) were run
to demonstrate the absence of interferences.
2.6.2. Recovery
The 3α-Hydroxy Tibolone recovery was evaluated by calculating
the mean of the area ratio of the six replicates of each QCL(0.280 ng/mL), QCM1 (4.500 ng/mL), QCM2 (12.500 ng/mL),
QCH (26.250 ng/mL) concentration and dividing the extracted
sample mean area ratio by the unextracted (Aqueous sample)
sample area ratio of the corresponding concentration.
2.6.3. Precision and accuracy
Precision and accuracy of the method were evaluated using three
different batches of quality control sample at concentrations of
0.280, 4.500, 12.500, 26.250 ng/mL and also including the lowest
limit of quantiﬁcation (LLOQ), 0.100 ng/mL. Each batch was
quantiﬁed with a speciﬁc calibration curve. For intra-batch assay
precision and accuracy, six replicates of quality control samples at
ﬁve concentration levels were assayed all at once within a day to
obtain CV (%) and accuracy values. The inter-batch assay
precision and accuracy were determined by analyzing mean values
of quality control sample from three plasma batches to obtain the
corresponding inter-batch CV(%) and accuracy values.
2.6.4. Sensitivity
The LLOQ was determined for 3α-Hydroxy Tibolone, based on two
criteria:(a) the analyte response as LLOQ had to be at least ﬁve times
base line noise and (b) the analyte response at LLOQ being
determined with precision of 720% and accuracy of 80–120%.
2.7. Matrix effect
It is either ion enhancement or suppression due to co-eluting matrix
components at the retention time and MRM of the analyte and IS.
Quantitative assessment of matrix effect provides useful information in
validation of MS based bioanalytical methods. As it is not possible to
completely eliminate the effect of matrix, the consistency (%CV) in
matrix effect is checked in different plasma sources (relative matrix
effect). The precision (%CV) should be ≤15% for the area ratio of
analyte/IS at each level for relative matrix effect [17].
Ion suppression/enhancement effects on the MRM LC–MS/MS
sensitivity can be checked by the post-column analyte infusion
experiment. A standard solution of analyte (at MQC level) is to be
infused post-column via a ‘T’ connector into the mobile phase at
10 mL/min and aliquot of extracted control plasma is then injected
into the column by the autosampler and MRM LC–MS/MS
chromatogram is to be acquired for analyte. Any dip in the
baseline upon injection of double blank plasma (without IS)
indicates ion suppression, while a peak at the retention time of
analyte indicates ion enhancement. Absolute matrix effect (ME)
was assessed by comparing the mean area ratio response of
unextracted samples (spiked after extraction) with mean area of
neat standard solutions (in mobile phase).
2.8. Hemolysis effect
It was performed to assess the impact of hemolysed human plasma
on the accuracy and precision of the assay. Six replicates of QCL
and QCH were prepared in hemolysed plasma and analyzed
against calibration curve spiked in normal plasma.
2.9. Stability
All stability tests of 3α-Hydroxy Tibolone were performed in
human plasma using six replicates of plasma spiked with 3α-
Hydroxy Tibolone at QCL and QCH levels except for stock
solution stability that was performed at aqueous QCM2 level.
Fig. 1 Parent ion spectra (upper trace) and product ion spectra (lower trace) of 3α-Hydroxy Tibolone.
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−70 1C), bench top stability (room temperature), autosampler
stability (5 1C), dry extract stability (2–8 1C), long term storage
stability in plasma (−70 1C), and stock solution stability (room
temperature)2.10. Pharmacokinetics and statistical analysis.
The analytical method developed here was applied to evaluate
comparatively the 3α-Hydroxy Tibolone plasma concentration
from two formulations of Tibolone tablet 2.5 mg, in normal,
healthy, adult, post-menopausal/surgical menopause female human
subjects under fasting conditions.
Fifty healthy female volunteers were selected for study after
assessment of their health status by clinical evaluation (physicalexamination, ECG) and routine laboratory tests. Bioequivalence
between the two formulations was assessed by calculating
individual test/reference ratios for the peak of concentration
(Cmax), area under the curve (AUC) of plasma concentration until
the last concentration observed (AUClast) and the area under the
curve between the ﬁrst sample (pre-dose) and the inﬁnite sample
(AUC0-inf).
Cmax and the time taken to achieve this concentration (tmax)
were obtained directly from the curves. The areas under the 3α-
Hydroxy Tibolone plasma concentration vs. time curves from zero
to the last detectable concentration (AUClast) were calculated by
applying the linear trapezoid rule. Statistical calculations were
deﬁned at the level of p≤0.05 and bioequivalence for the two
formulations was concluded as the 90.0% conﬁdence interval of
3α-Hydroxy Tibolone falls within the acceptable range of 80.00–
125.00% for Cmax, AUC0-t and AUC0-inf, deﬁned by both the US
Fig. 2 Parent ion spectra (upper trace) and product ion spectra (lower trace) of 3α-Hydroxy Tibolone-13CD3.
V.P. Shinde et al.274Food and Drug Administration (FDA) [18,19] and the National
Sanitary Surveillance Agency (ANVISA) [15]. The software used
for statistical analysis was SAS software version 9.2.2.11. Incurred sample reanalysis
The assay reproducibility was demonstrated by reanalysis of 5% of
total subject samples on completion of subject sample analysis and
difference between initial and repeated concentration was found to
be within 715%.3. Results and discussion
3.1. Method development
The goal of this work was to develop and validate a simple, rapid,
selective and sensitive method for the quantitative determination of
3α-Hydroxy Tibolone in plasma samples. For this MS optimiza-
tion was done by direct infusion of derivatized products of 3α-
Hydroxy Tibolone and its deuterated IS. For detection MRM was
generated for the analyte and IS as it is more selective, sensitive
and reliable than SIM mode detection [20].
Fig. 4 MRM chromatograms of (A) blank normal human plasma and
(B) 3α-Hydroxy Tibolone at LOQ concentration (0.100 ng/mL).
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sensitivity in negative ESI mode [14]. The concentration of PTSI
also plays an important role in derivatization and it was observed
that the concentration of PTSI reported by Zuo et al. [14] for
derivatization did not give the desired product. It was optimized to
1% PTSI in acetonitrile to get the desired derivatized product and
the amount to be added in each sample was also optimized to
50 mL to get the best result in terms of sensitivity. The solvent
used for preparation of stock solution and working solution is
important as it is observed that the solvent containing OH group
does not allow the derivatization process due to strong afﬁnity of
PTSI towards OH group. Therefore, stock and working solutions
of analyte and IS were prepared in pure acetonitrile.
Chromatographic conditions, especially the composition of the
mobile phase and selection of suitable column, were optimized
through several trials to achieve the best resolution and highest
signals of analyte and IS. Separation science was revolutionized
with the introduction of UPLC and the use of acquity column with
1.7 mm particle size enabled us to achieve the best resolution,
speed and sensitivity during the analysis. Two stereoisomers 3α-
Hydroxy Tibolone and 3β-Hydroxy Tibolone were separated using
analytical column ACQUITY UPLC® BEH C18 1.7 mm
(2.1 mm 100 mm). Fig. 3 shows actual separation of two
metabolites in subject sample.
Liquid–liquid extraction method was optimized for the extrac-
tion of analyte and IS from plasma samples. Addition of 2 mM
ammonium acetate to stop the derivatization instead of water also
helps to get the maximum sensitivity at LLOQ level. The UPLC–
MS/MS method described here for drug quantiﬁcation and
separation is in accordance with National Sanitary Surveillance
Agency (ANVISA) [15] and US Food and Drug Administration
requirements [16].3.2. Linearity and selectivity
The simplest regression method for the calibration curves of 3α-
Hydroxy Tibolone was Y¼mXþC from 0.100 to 35.000 ng/mL.
Correlation coefﬁcient ranged from 0.9993 to 0.9997. The LLOQ
was 0.100 ng/mL. The chromatograms obtained from the LLOQ
and extracted blank plasma are presented in Figs. 4 and 5. 3α-
Hydroxy Tibolone and IS retention times were around
3.270.5 min and 3.170.5 min respectively. The signal to noise
ratio was higher than 6. In the case of 3α-Hydroxy Tibolone and
its IS, no signiﬁcant interference was obtained at their respective
retention times when six different lots of normal blank humanFig. 3 Chromatogram showing the separation of two metabolites in
actual subject sample.
Fig. 5 MRM chromatograms of (A) blank normal human plasma and
(B) 3α-Hydroxy Tibolone-13CD3.plasma, two different lots each of hemolysed and lipemic blank
human plasma with K3-EDTA as an anticoagulant were processed
and evaluated against six extracted LLOQ samples. Furthermore,
blank plasma samples from all volunteers were run before
unknown concentration sample quantiﬁcation showing a clear
chromatogram in all cases.
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Absolute recoveries were evaluated for 3α-Hydroxy Tibolone and
its IS in terms of peak area ratio. Recovery (%) and % CV for
QCL, QCM1, QCM2, and QCH were as follows: 89.20 and 6.34,
95.29 and 1.93, 97.16 and 2.22, 94.78 and 1.98, respectively.3.4. Accuracy and precision
Intra-batch precision and accuracy of the assay were measured for
3α-Hydroxy Tibolone at each QC level (0.280, 4.500, 12.500,
26.250 ng/mL). Calculated inter-batch precision and accuracy of
the method ranged from 1.94% to 5.78% and 98.93% to 101.55%
respectively as presented in Table 1. These results were within the
acceptance criteria for precision and accuracy i.e., deviation values
within 715% of the nominal values, except for LLOQ which
could show a 720% deviation. The LLOQ was validated as
0.100 ng/mL, showing intra-batch precision and accuracy of the
method as 10.83% and 94.00% respectively.3.5. Matrix effect
The relative matrix effect was checked and %CV was 1.92 at LQC
and 0.49 at HQC level. As the precision is within the acceptance
criteria, it is concluded that the matrix effect is consistent and precise.3.6. Hemolysis effect
The precision and accuracy of quality control samples at QCL and
QCH levels were found to be within acceptance criteria; hence it
was concluded that hemolysis effect is absent.Table 1 Accuracy and precision data for 3α-Hydroxy Tibolone qua
QC samples Nominal conc. (ng/mL) Accuracy
Intra-batch assaya
QC-LLOQ 0.100 94.00
QCL 0.280 98.57
QCM1 4.500 101.16
QCM2 12.500 100.75
QCH 26.250 102.83
a(n¼6), expressed as (found concentration/nominal concentration) 100
bValues obtained from all three runs (n¼18).
Table 2 Arithmetic mean pharmacokinetic parameters obtained from
formulation.
Parameters Test formulation
Mean SD
Cmax (ng/mL) 5.74 2.3
tmax (h) 1.88 0.8
t1/2 (h) 6.94 2.1
AUC last (ng h/mL) 23.23 7.8
AUC0-inf (ng h/mL) 24.95 8.13.7. Stability of 3α-Hydroxy Tibolone
The stability test of 3α-Hydroxy Tibolone in human plasma
showed no signiﬁcant degradation, when kept on bench at room
temperature for 9 h before processing. The percentage difference
for low and high QC samples was 3.10 and −1.58 respectively.
For ﬁve freeze–thaw cycles it was −5.72 and −9.11. Extracted
samples of 3α-Hydroxy Tibolone were stable for 56 h when kept
in autosampler at 5 1C and the percentage difference for QCL and
QCH was 1.47 and −4.51 respectively. Dry extracted samples
were stable for 28 h at 2–8 1C and the percentage difference was
−8.97 and −13.96 for QCL and QCH respectively.
Stock solution of 3α-Hydroxy Tibolone was found to be stable
for 23 h at room temperature and the percentage difference was
2.57, whereas it was stable for 10 days at 2–8 1C and the
percentage difference was −1.81.These stability experiments were
performed at medium QC level. 3α-Hydroxy Tibolone was stable
in plasma at −70 1C for 126 days.
3.8. Comparative pharmacokinetic parameters
A total of 50 volunteers ﬁnished the study. Table 2 shows the
values of pharmacokinetic parameters of both formulations (test
and reference formulations).4. Conclusion
This work describes a fast, sensitive and robust method to quantify
3α-Hydroxy Tibolone in human plasma using 3α-Hydroxy Tibo-
lone-13CD3 as an internal standard. Extracted samples were
analyzed by UPLC–ESI-MS/MS. This method agrees with the
requirements proposed by the US Food and Drug Administrationntiﬁcation in human plasma.
Precision
Inter-batch assayb Intra-batch assaya Inter-batch assayb
103.00 10.83 12.50
98.93 5.80 5.78
98.96 1.27 2.85
99.90 1.69 1.94
101.55 1.89 2.42
.
50 volunteers after administration of each of 2.5 mg Tibolone tablet
Reference formulation
Mean SD
3 5.67 2.42
8 1.89 0.82
4 7.18 2.61
6 24.02 9.26
4 25.67 9.45
Application of UPLC–MS/MS for separation and quantiﬁcation of 3a-Hydroxy Tibolone 277and ANVISA of high sensitivity, selectivity and high sample
throughput in comparative pharmacokinetic assays such as bioe-
quivalence studies. The lowest concentration quantiﬁed was
0.100 ng/mL with suitable accuracy and precision. The intra-
assay precision ranged from 1.27% to 10.83% while inter-assay
precision ranged from 1.94% to 12.50%. The intra-assay accuracy
ranged from 94.00% to 102.83% while inter-assay accuracy
ranged from 98.93% to 103.00%. The described method for
separation and quantiﬁcation of 3α-Hydroxy Tibolone in human
plasma was successfully applied in bioequivalence study of two
2.5 mg Tibolone tablet formulations using an open, randomized,
two-period, cross-over design.
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